<DOC>
	<DOC>NCT02821312</DOC>
	<brief_summary>This study is a Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Oral Administration of DA-8010 in Healthy Subjects.</brief_summary>
	<brief_title>A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects</brief_title>
	<detailed_description>This study will be a randomised, double-blind, placebo-controlled, dose-escalation, single and multiple oral dose study conducted in 2 parts. In Part A, each subject will participate in 1 treatment period only and reside at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 3 (48 hours postdose), except for Group A4, where each subject will participate in 2 treatment periods separated by a minimum of 13 days to evaluate the effect of food. In Part B, each subject will participate in 1 treatment period only and reside at the CRU from Day -1 (1 day before dosing) until the morning of Day 9 (48 hours after the final dose on Day 7).</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<criteria>BMI between 18.0 and 32.0 kg/m2 Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions Subjects who do not agree to use a method of acceptable contraception Female subjects of childbearing potential who do not agree to use a highly effective method of birth control Consume more than 28 or 21 units of alcohol per week if male or female, respective Subjects who have used nicotinecontaining products (including cigarettes), within 3 months prior to the first dose administration Subjects who have used, or intend to use the product like nonprescribed systemic or topical medication, herbal remedy, vitamin/mineral supplement, within 7 days of the first dose administration Systolic blood pressure &lt; 90 mmHg or &gt; 140 mmHg Diastolic blood pressure &lt; 50 mmHg or &gt; 90 mmHg Pulse rate &lt; 45 bpm or &gt; 100 bpm Positive urine drugs of abuse screen at screening or first admission Positive alcohol breath test at screening or first admission Positive cotinine test at screening or first admission Abnormality in the 12lead ECG at screening, admission or predose on Day 1 Subjects who are pregnant, breastfeeding, or lactating Subjects who are still participating in another clinical study (e.g. attending followup visits) or who have participated in a clinical study involving administration of any investigational drug in the past 3 months prior to the first dose administration Subjects who have a significant history of drug allergy, as determined by the Investigator Aspartate aminotransferase and/or Alanine aminotransferase ≥ 1.5 × upper limit of normal (ULN) or total bilirubin &gt; ULN at screening or admission Subjects who are carriers of HBsAg or hepatitis C antibody, have serum hepatitis or positive result for the test for HIV antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>